Isotretinoin and intestinal inflammation: what gastroenterologists need to know
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
A possible aetiological role in the development or exacerbation of inflammatory bowel disease (IBD) has been suggested for a small number of drugs, including antibiotics,1 non-steroidal anti-inflammatory drugs (NSAIDs)2 and, more contentiously, oral contraceptive pills.3 Intriguing and less appreciated is the potential association of IBD with the use of the vitamin A analogue isotretinoin (13- cis -retinoic acid) which is widely prescribed in the treatment of severe acne. A small number of case reports have reported the development of IBD whilst receiving isotretinoin therapy.4–11 A review of adverse events reported to the United States Federal Drug Administration’s (FDA) Medwatch scheme over a 5 year period (1997–2002) revealed 85 cases of IBD, of which the causal association with isotretinoin was considered probable or highly probable in 73% of cases.12 It has been questioned whether this represents a true aetiological link, with the biggest confounder being the overlap in the peak age of the onset of IBD with the age group most commonly prescribed isotretinoin.13 Despite this there is biological plausibility in why such an association may exist. Retinoids have been shown to exhibit diverse effects on epithelial cell turnover, as well as glycoprotein and cytokine synthesis. More recently, advances in our understanding of the immunology of the gut have shown a fundamental role for retinoids in the regulation of the intestinal mucosal immune response. Here we discuss the literature on the association of isotretinoin therapy with intestinal inflammation and IBD, present an update of epidemiological and pharmaco-vigilance data, and highlight possible underlying mechanisms, based upon recent advances in mucosal immunology. IBD has not been noted in clinical trials of isotretinoin in the treatment of acne, but the exposure length and number of patients in trials may not have been sufficient. The association has …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reciprocal T H 17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid
Mucida, D., Park, Y., Kim, G., Turovskaya, O., Scott, I., Kronenberg, M., & Cheroutre, H. (2007) · Science · doi:10.1126/science.1145697 · Cited by 1,982
Phenotypic and functional features of human Th17 cells
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì, L., Ferri, S., Frosali, F., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070663 · Cited by 1,861
Benson, M. J., Pino-Lagos, K., Rosemblatt, M., & Noelle, R. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070719 · Cited by 847
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Margolis, D. J., Fanelli, M., Hoffstad, O., & Lewis, J. D. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.303 · Cited by 177
Isotretinoin use and the risk of inflammatory bowel disease: a case-control study
Crockett, S. D., Porter, C. Q., Martin, C. F., Sandler, R. S., & Kappelman, M. D. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.124 · Cited by 161
Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study
Alhusayen, R. O., Juurlink, D. N., Mamdani, M. M., Morrow, R. L., Shear, N. H., & Dormuth, C. R. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.387 · Cited by 84
Liang, L., Qi, X., Jiang, X., Chen, T., & Dong, L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1340068 · Cited by 19
Metadata
- Authors
- Shale, M., Kaplan, G. G., Panaccione, R., & Ghosh, S.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2009-05-11
- Volume
- 58
- Issue
- 6
- Pages
- 737-741
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2040216256
- Cited by
- 44
- References
- 3
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.